Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 4, 2026

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.

Zacks Investment Research • Sep 1, 2026

22 best-performing stocks of August, as the software industry continues its recovery

The energy and technology sectors did well in August, while Moderna's stock was the best performer by a wide margin.

Market Watch • Aug 31, 2026

Wall Street Is Now Backing the Clarity Act. Here's the Most Likely Scenario for What Happens Next With Crypto.

According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.

The Motley Fool • Aug 27, 2026

Charles River Gains 88.6% in a Year: What's Driving the Rally?

CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.

Zacks Investment Research • Aug 21, 2026

CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?

Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

Zacks Investment Research • Aug 21, 2026

How an Insider CEO Is Taking a Fresh Look at Charles River

Even after 35 years and by her count 16 or 17 different jobs across every division at Charles River Laboratories, Birgit Girshick still made visiting the company's far-flung outposts one of her first priorities after taking over as CEO on May 5.

WSJ • Aug 20, 2026

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC's next-generation multivalent.

Business Wire • Aug 20, 2026

International Markets and Charles River (CRL): A Deep Dive for Investors

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Zacks Investment Research • Aug 10, 2026

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.

MarketBeat • Aug 6, 2026